Oppenheimer raised the firm’s price target on Guardian Pharmacy (GRDN) to $43 from $38 and keeps an Outperform rating on the shares following the company’s earnings report. Overall, the results reflect Guardian’s effort to offset the IRA impact, which will allow investors to return their focus to the strong underlying growth tailwinds, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy files automatic Class A common stock offering
- Guardian Pharmacy reports Q1 EPS 29c, consensus 24c
- Guardian Pharmacy affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
- Guardian Pharmacy initiated with a Buy at BofA
- Guardian Pharmacy price target raised to $43 from $38 at Truist